Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer
View abstract on PubMed
Summary
This summary is machine-generated.Galectin-8 and Galectin-9 expression in endometrial cancer (EC) correlates with patient survival. Cytosolic Galectin-8 is a positive prognostic factor for overall survival and progression-free survival in EC patients.
Area Of Science
- Oncology
- Molecular Biology
- Gynecologic Oncology
Background
- Endometrial cancer (EC) is a prevalent gynecological malignancy with limited therapeutic options in advanced stages.
- Galectins are implicated in various cellular processes and their expression is elevated in several tumor types.
- Large-scale studies investigating galectin expression in EC are currently limited.
Purpose Of The Study
- To investigate the expression of Galectin-8 (Gal-8) and Galectin-9 (Gal-9) in endometrial cancer tissues.
- To correlate galectin expression with histopathological variables and patient survival outcomes.
Main Methods
- Immunohistochemical staining was performed on 225 endometrial cancer patient specimens using antibodies for Gal-8 and Gal-9.
- Expression levels and localization (cytosolic and nuclear) of Gal-8 and Gal-9 were analyzed.
- Statistical correlation between galectin expression and histopathological variables, overall survival (OS), and progression-free survival (PFS) was assessed.
Main Results
- Cytosolic expression of both Gal-8 and Gal-9 was associated with tumor grading and patient survival.
- Cytosolic Gal-8 expression emerged as a significant positive prognostic factor for both OS and PFS.
- Nuclear Gal-8 expression correlated with OS, while cytosolic Gal-9 correlated with improved OS.
Conclusions
- Galectin-8 and Galectin-9 expression, particularly in the cytosol, are associated with survival outcomes in endometrial cancer.
- These findings suggest galectins as potential prognostic biomarkers for EC.
- Further research is warranted to elucidate the molecular mechanisms underlying the role of galectins in EC progression.

